Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What are the treatment options for patients with duodenal cancer who has progressed on FOLFIRINOX and what are the quality of evidence behind this.
Related Questions
Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?
Do you offer a curative surgery (Whipple procedure) to patients with duodenal adenocarcinoma, with 2-5 liver metastases, and with near CR after 3-6 months of FOLFOX chemotherapy?
How was treatment response assessed on the PROSPECT trial?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
For a pedunculated rectal polyp found to be adenocarcinoma after endoscopic removal, with PNI as the only adverse feature, would you recommend additional treatment such as surgery or chemoradiation?
What grade 3 toxicities would you expect sufficient overlap between capecitabine and 5-fluorouracil that you would avoid substituting one over the other?
How does the management of POLE mutated colorectal cancer differ from that of dMMR/MSI high disease?
In patients with resected PDAC treated with adjuvant FOLFIRINOX who recur from 1-3 years post completion of adjuvant therapy, do you consider retreatment with FOLFIRINOX or gemcitabine/nab-paclitaxel in the absence of a clinical trial?
Do you give adjuvant chemotherapy for an incidental cholangiocarcinoma found at time of liver transplant (done for HCC or other reason) in the explanted liver?
Is there a role of adjuvant or systemic therapy for patients with resected stage I colon cancer with subsequent local recurrence S/P a second resection and now has NED?
